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Micafungin is considered an important agent for the treatment of invasive fungal infections in the intensive care unit
(ICU). Little is known on the pharmacokinetics of micafungin. We investigated micafungin pharmacokinetics (PK) in ICU
patients and set out to explore the parameters that influence micafungin plasma concentrations. ICU patients receiving
100 mg of intravenous micafungin once daily for suspected or proven fungal infection or as prophylaxis were eligible.
Daily trough concentrations and PK curves (days 3 and 7) were collected. Pharmacokinetic analysis was performed using a
standard two-stage approach. Twenty patients from the ICUs of four hospitals were evaluated. On day 3 (n 20), the me-
dian (interquartile range [IQR]) area under the concentration-time curve from 0 to 24 h (AUC0–24) was 78.6 (65.3 to 94.1)
mg · h/liter, the maximum concentration of drug in serum (Cmax) was 7.2 (5.4 to 9.2) mg/liter, the concentration 24 h after
dosing (C24) was 1.55 (1.4 to 3.1) mg/liter, the volume of distribution (V) was 25.6 (21.3 to 29.1) liters, the clearance (CL)
was 1.3 (1.1 to 1.5) liters/h, and the elimination half-life (t1/2) was 13.7 (12.2 to 15.5) h. The pharmacokinetic parameters on
day 7 (n 12) were not significantly different from those on day 3. Daily trough concentrations (day 3 to the end of ther-
apy) showed moderate interindividual (57.9%) and limited intraindividual variability (12.9%). No covariates of the influ-
ence on micafungin exposure were identified. Micafungin was considered safe and well tolerated. We performed the first
PK study with very intensive sampling on multiple occasions in ICU patients, which aided in resolving micafungin PK.
Strikingly, micafungin exposure in our cohort of ICU patients was lower than that in healthy volunteers but not signifi-
cantly different from that of other reference populations. The clinical consequence of these findings must be investigated
in a pharmacokinetic-pharmacodynamic (PK-PD) study incorporating outcome in a larger cohort. (This study is registered
at ClinicalTrials.gov under registration no. NCT01783379.)
The incidence of fungal infections continues to pose a seriousthreat in the intensive care unit (ICU) and is associated with a
high mortality rate and prolonged duration of ICU and hospital
stay (1–4). Almost 20% of all isolated pathogens in ICU patients
are determined to be fungi, with Candida species accounting for
the majority of fungal infections (1).
Echinocandins are currently considered the primary treatment
for patients with invasive candidiasis or candidemia (5, 6). Mica-
fungin is an intravenous antifungal agent of the echinocandin
class that exerts potent in vitro and in vivo activity against both
Candida and Aspergillus species (7–10). In the clinical setting, mi-
cafungin has demonstrated efficacy in treating invasive candidia-
sis and candidemia (11, 12).
ICU patients may be subject to severely altered pharmacoki-
netic (PK) characteristics compared to those of non-critically ill
patients. In this population, physiological changes, such as organ
failure (hepatic and/or renal dysfunction), with the consequence
of an altered drug volume of distribution (V) and/or clearance
(CL), the use of organ support (i.e., renal replacement therapy
and/or extracorporeal membrane oxygen [ECMO]), and interact-
ing comedications may result in highly varied pharmacokinetics
of drugs, including antimicrobial agents (13, 14). In addition, V
and CL may be subject to increased inter- and intrasubject vari-
ability due to altered plasma protein binding (15). Also, it has been
hypothesized that disease severity might result in altered drug PK
behavior (16).
The PK of micafungin is very well defined in non-critically ill
patients. Micafungin exhibits linear PK over a wide dosage range
in adults, with steady state being reached by day 4, without the
need for a loading dose (17). Specifically, dose adaptations are not
required in patients with renal or hepatic impairment and renal
replacement therapy (18–22). Nevertheless, there are very limited
data available on micafungin PK in ICU patients; thus, it remains
unclear whether the PK is altered in this population of critical ill
patients due to the above-mentioned aspects.
We set up this study to describe the PK of micafungin in ICU
patients and explore the parameters of influence on interindividual
variability in micafungin plasma concentrations. This study aids in
obtaining more knowledge on drug behavior in a group of highly
vulnerable patients.
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MATERIALS AND METHODS
Study design. We performed an open-label, multiple-dose, and multi-
center observational PK study of micafungin in adult ICU patients (reg-
istered at ClinicalTrials.gov under registration no. NCT01783379). Our
study was conducted in accordance with the Declaration of Helsinki and
good clinical practice regulations. The study was carried out in The Neth-
erlands in accordance with applicable rules concerning the review of re-
search ethics committees and informed consent. The study was conducted
from January until December 2013 in the ICUs of the Radboud University
Medical Center (Nijmegen), Canisius Wilhelmina Hospital (Nijmegen),
Rijnstate Hospital (Arnhem), and Erasmus Medical Center (Rotterdam),
The Netherlands.
Study population.Patients admitted to the ICU to receive micafungin
for suspected or proven fungal infection were eligible if they met the
following inclusion criteria:18 years of age on the day of the first mica-
fungin dose, not receiving micafungin treatment for 2 days before en-
rollment, and having a central venous or arterial catheter. Patients were
excluded who had history of hypersensitivity to echinocandins or excipi-
ents similar to those found in the micafungin preparation, HIV or hepa-
titis B/C infection, or abuse of alcohol or drugs. An empirical sample size
of 20 evaluable patients was selected to adequately define micafungin PK
(23).
Treatment. All patients received 100 mg of micafungin once daily by
intravenous infusion over 1 h (18). Micafungin therapy continued as long
as was considered clinically relevant by the treating physician. Yet, for the
purpose of this study, PK sampling was limited to a maximum of 14 days,
with an additional 3 days after cessation of therapy.
Baseline parameters. At screening (day 0 of study), the following pa-
rameters were registered: age, gender, race, weight, height, body mass
index (BMI), fat free mass (FFM) (as calculated according to Janmahasa-
tian et al. [24]), relevant comedication(s), medical history, indication for
admission to the ICU, indication for micafungin use, relevant abnormal-
ities (e.g., type of renal replacement therapy, mechanical ventilation, ex-
cess body fluid), or acute physiology and chronic health evaluation II
(APACHE II), sequential organ failure assessment (SOFA), and Child-
Pugh score. During the study, patient comedications, clinical characteris-
tics, and relevant abnormalities were recorded on all study days. In addi-
tion, on days on which PK was measured (i.e., days 3 and 7), weight, BMI,
FFM, SOFA score, and Child-Pugh score were documented. Microbiolog-
ical data were obtained throughout the study as part of routine patient
care.
Vital signs were monitored immediately before and after micafungin
infusion and hourly for the first 4 h afterwards on days on which PK was
measured.
Laboratory data. Blood was sampled three times a week and on days
on which PK was measured for the determination of biochemical and
hematological parameters, including serum electrolytes, total protein, al-
bumin, blood urea nitrogen (BUN), aspartate aminotransferase (ASAT),
alanine aminotransferase (ALAT), gamma-glutamyl transferase (GGT),
alkaline phosphatase (AP), total bilirubin, C-reactive protein (CRP), lac-
tate dehydrogenase (LDH), triglycerides, creatinine kinase, creatinine, he-
moglobin, hematocrit, white blood cell differential, and platelet count.
Pharmacokinetic sampling. At day 3 (1 day) of treatment, a PK
curve of 10 samples was drawn with sampling times (t) of 0 (predose), 0.5,
1 (end of infusion), 2, 4, 6, 8, 12, 18, and 24 h postinfusion. A second PK
curve of six samples was drawn on day 7 with sampling t of 0 (predose), 1,
4, 8, 12, and 24 h postinfusion. On all study days up until day 14, trough
concentrations 24 h after dosing (C24) were drawn until 3 days after ces-
sation of therapy. Patients were considered evaluable if at least the first PK
curve on day 3 was completed. Blood samples (2 ml) were collected
from an indwelling arterial catheter in lithium-heparin-containing tubes
(nongel) and stored immediately at 4°C. Within 48 h after collection,
samples were centrifuged at 1,900  g for 5 min. Plasma was aspirated,
directly transferred to polypropylene tubes, and stored at80°C.
Safety. In addition to clinical observations, adverse events were re-
ported on all study days. Local researchers and physicians determined a
potentially causal relationship with micafungin administration.
Analytical assay for micafungin. After pretreatment with a protein
precipitation solution (50% acetonitrile, 50% methanol, and 0.1% formic
acid), analysis was performed with a validated ultraperformance liquid
chromatography (UPLC) method, using a fluorescence detector (dy-
namic range for micafungin, 0.01 to 32.40 mg/liter; concentration-depen-
dent accuracy range [n  15], 97.61% to 101.64%). Intraday precision
ranged between 1.41% and 5.14% (n 5). In addition, interday precision
varied between 0.69% and 2.20% (n  15). A stability analysis of mica-
fungin in whole blood confirmed that micafungin was stable for a mini-
mum of 7 days at 4°C (mean concentration  standard deviation [SD],
98.56% 1.91%, n 4).
Micafungin PK data analysis. Pharmacokinetic parameters (area un-
der the concentration-time curve from 0 to 24 h [AUC0 –24], maximum
concentration of drug in serum [Cmax], C24, half-life [t1/2], volume of
distribution [V], clearance [CL], and terminal elimination rate constant
[kel]) were calculated using noncompartmental analysis (Phoenix version
6.3). The AUC0 –24 was calculated using the linear up-log down trapezoi-
dal rule. In addition, Cmax and C24 were directly observed from the data.
Half-life was calculated by ln 2/kel, in which kel was determined by linear
regression of the terminal points of the log-linear plasma concentration-
time curve.Vwas calculated using the formula dose/AUC · kel, and CL was
calculated as dose/AUC0 –24.
A paired t test was performed on the log-transformed pharmacoki-
netic parameters of days 3 and 7 in order to detect statistically significant
differences over time. Geometric mean ratios (GMRs) with a 90% confi-
dence interval (CI) falling entirely within the range of 0.80 to 1.25 were
considered to indicate no significant differences in pharmacokinetic pa-
rameters. Linear regression was performed to determine the relationships
between the log-transformed pharmacokinetic parameters AUC0 –24, CL,
and V and covariates (i.e., gender, age, weight, [plus related parameters
BMI and FFM]), renal replacement therapy, APACHE II score, SOFA
score, Child-Pugh score, liver enzyme levels (ALAT, ASAT, AP, bilirubin,
GGT, and LDH), and other laboratory parameters (albumin, BUN, cre-
atinine, and CRP levels). Statistical analyses were performed using SPSS
version 20.0 (SPSS, Inc., Chicago, IL, USA). A P value of0.05 was con-
sidered statistically significant.
RESULTS
Patients. Twenty-eight patients were included from the ICUs of
three Dutch hospitals. The fourth hospital did not achieve inclu-
sion of evaluable patients. Twenty patients completed the first PK
curve on day 3 and were evaluable for analysis. The remaining 8
patients were withdrawn from the study before day 3 due to the
removal of a central venous catheter (n 3), switch to fluconazole
(n  1), and death (n  4). Baseline demographics (n  20) are
available in Table S1 in the supplemental material. Micafungin
was administered as treatment for suspected or proven fungal in-
fections (n 19) or prophylaxis against fungal infections (n 1)
caused by Candida spp., Aspergillus spp., or both. Three patients
received micafungin therapy for longer than the initial study du-
ration of 14 days. In the remaining 17 patients, study participation
was discontinued due to clinical response before day 14 (n  4),
removal of central venous catheter (n 4), switch to fluconazole
(n 2), discharge to another ward (n 2), or death (n 5).
Micafungin pharmacokinetics. Subjects received a median of
7 micafungin doses once daily (range, 3 to 14), resulting in a total
of 20 PK curves on day 3 and 12 PK curves on day 7 (see Table S1
in the supplemental material). A total of 371 samples for PK anal-
ysis were drawn. One aberrant concentration was observed in a
single patient (18.9 mg/liter at t of 19.98 h). Using Grubbs’ test for
Lempers et al.
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outliers, this single data point was excluded for further analysis (Z,
3.93; critical Z, 2.68; n 19).
The median and interquartile range (IQR) (25 to 75%)
AUC0 –24 on days 3 and 7 were 78.6 (65.3 to 94.1) mg · h/liter and
65.7 (55.9 to 88.7) mg · h/liter, respectively. The median (IQR)
Cmax was 7.2 (5.4 to 9.2) mg/liter on day 3 and 6.2 (5.1 to 9.2)
mg/liter on day 7. The median (IQR) C24 was 1.6 (1.4 to 3.1)
mg/liter on day 3 and 1.6 (1.3 to 2.4) mg/liter on day 7. An over-
view of all pharmacokinetic parameters of micafungin on days 3
and 7 is shown in Table 1 and Fig. 1, 2, and 3. Daily trough con-
centrations over time are shown in Fig. 4. At the start of therapy,
the median C24 at t of 24 h differed significantly from that at t of 48
h (P  0.009), whereas the median C24 at t of 48 h did not differ
significantly from that at t of 72 h. No significant difference in C24
at later time points was seen.
The GMR for AUCday7/AUCday3 was 0.97 (90% CI, 0.85 to
1.11). In addition, the GMRs for Cmax and C24 were 0.94 (90% CI,
0.81 to 1.10) and 0.87 (90% CI, 0.59 to 1.28; Table 1), respectively.
The median interindividual coefficient of variation (CV) of mica-
fungin trough concentrations (day 3 to the end of therapy)
amounted to 57.9% (95% CI, 57.7 to 58.2; 92 samples) and the
median intraindividual CV to 12.9% (95% CI, 12.7 to 13.2; n 
16) over the same period. The micafungin C24 correlated well with
AUC on day 3 (r2 0.919, P 0.01) and day 7 (r2 0.983, P
0.01) (see Fig. S1 in the supplemental material).
Covariates. The micafungin PK parameters AUC0 –24, CL, and
V on days 3 and 7 were not significantly influenced by specific
covariates (gender, age, weight [including BMI and FFM], renal
replacement therapy, APACHE II score, SOFA score, Child-Pugh
score, liver function enzyme levels [ALAT, ASAT, AP, bilirubin,
GGT, and LDH]) and other laboratory parameters (albumin,
BUN, creatinine, and CRP levels). No interacting comedication
was identified throughout the course of treatment.
Safety. After the start of micafungin dosing, 18/20 subjects
(90%) experienced a total of 65 new or aggravated clinical adverse
events (AEs) during follow-up. Five serious AEs were reported
(persistent infections due to anastomotic leak, renal failure, met-
abolic acidosis, thrombosis, and the need for vasoactive drugs),
leading to the death of these five subjects. It was concluded that
these serious AEs were not related to the administration of mica-
fungin. Of the reported 65 AEs, four were categorized as possibly
related to micafungin therapy (elevated liver function enzymes,
reported as an increase of 3 times the upper limit of normal).
None of these AEs resulted in modifications or discontinuation of
micafungin therapy.
DISCUSSION
To our knowledge, this cohort of ICU patients is unique in size
and sampling intensity with PK curves on multiple occasions and
daily trough concentrations over the complete course of treat-
ment. It reflects a real-life situation with a population being
treated for fungal infections. This aided us in describing the PK of
micafungin in a cohort that is frequently subject to altered PK.
Strikingly, we found much lower exposure in this cohort of
ICU patients than the exposure described in the literature. Using
an unpaired t test (on mean exposure standard deviation [SD]
and number of patients), the exposure in this cohort appeared to
be significantly lower than that in healthy volunteers (20, 25–27).
A statistical comparison with other patient populations did not
yield a significant different AUC (19, 20, 22, 27, 28) (see Table S2
in the supplemental material). This might suggest a negative im-
pact of disease on the exposure of micafungin. We found 57.9%
interindividual variability in micafungin C24. To our knowledge,
interindividual variability in micafungin C24 in ICU patients has
not been reported prior to this study. In comparison, caspofungin
interindividual variability in ICU patients was reported to be
45.6% (n 21) in a study from our group and 57% (n 6) in the
TABLE 1 Micafungin pharmacokinetics on day 3 and day 7
Parameter
PK curve on day (median [IQR]):
3 (n 20) 7 (n 12)
AUC0–24 (mg · h/liter) 78.6 (65.3–94.1) 65.7 (55.9–88.7)
Cmax (mg/liter) 7.2 (5.4–9.2) 6.2 (5.1–9.2)
C24 (mg/liter) 1.6 (1.4–3.1) 1.6 (1.3–2.4)
t1/2 (h) 13.7 (12.2–15.5) 14.4 (12.8–16.3)
V (liters) 25.6 (21.3–29.1) 28.7 (16.8–32.1)
CL (liters/h) 1.3 (1.1–1.5) 1.5 (1.2–1.8)
kel (1/h) 0.05 (0.04–0.06) 0.05 (0.04–0.05)
FIG 1 Mean plasma concentration (conc.)–time curve of micafungin (100 mg/day) on day 3.
Micafungin PK in ICU Patients
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Defining Antibiotic Levels in Intensive Care Unit Patients (DALI)
study (14, 29).
We can think of four possible explanations for the lower expo-
sure of micafungin: (i) altered protein binding, (ii) changes in
metabolic route, (iii) impact of disease severity, and (iv) a higher
average body weight in this cohort than in reference populations.
These are discussed below.
(i) As a general rule, an increased free fraction due to protein
displacement will lead to a lower total drug exposure (30). Mica-
fungin is highly protein bound (99%). Hence, a lower exposure
due to lower protein binding (a higher free fraction) is possible.
This would also match previous findings in subjects with severe
hepatic dysfunction and findings with caspofungin (27, 31). Due
to the limited variability in albumin status (all were hypoalbumin-
emic), we could not make a distinction between micafungin ex-
posure in patients with normal albuminemia versus hypoalbu-
minemia. Unfortunately, no unbound micafungin plasma
concentrations were analyzed; thus, protein displacement cannot
be confirmed or rejected as a possible cause for the lower expo-
sure.
(ii) In patients with severe hepatic dysfunction, lower exposure
of micafungin parent compound and higher and more variable
plasma concentrations of the M-5 metabolite were reported (27).
This has also been confirmed in younger patients (32). The au-
thors suggested this was due to either a higher rate of formation or
lower CL of the M-5 metabolite. Decreased clearance of the M-5
metabolite seems the most plausible explanation, but increased
formation of the M-5 metabolite is a possible explanation for
lower micafungin exposure. We did not measure the exposure of
micafungin metabolites and therefore were unable to confirm this
as a possible explanation.
(iii) This ICU population was heterogeneous in terms of
APACHE II and SOFA scores. For anidulafungin, it has been
hypothesized that exposure is lower for patients with a higher
disease severity score, although this correlation did not reach
statistical significance (16). For caspofungin, an identical study
by our group demonstrated that disease severity did not impact
exposure (29). For micafungin, disease severity (both APACHE
II and SOFA scores) did not reveal a correlation with exposure
and therefore can be ruled out as a possible cause for the low
exposure.
(iv) Last, Gumbo et al. (33) demonstrated that micafungin
systemic clearance in bone marrow transplant patients increased
as a function of body weight of66.3 kg. Recently, a formula has
been proposed to individualize micafungin doses for overweight
and obese patients (34). Body weight and other weight-derived
parameters, BMI and FFM, were not identified as covariates in this
study, possibly a result of the average weight in this study being
close to the ideal body weight. Also, the weight distribution in the
current study was comparable to that in other studies, thereby
ruling out a relatively high body weight as a possible cause for the
low exposure.
In addition to the above findings, these data suggest that
steady-state concentrations of micafungin are reached by day 3 at
the latest, which is consistent with previous reports (18, 35). At the
initiation of micafungin therapy, the C24 at 24 h was significantly
lower than that at 48 h (but not comparing t of 48 h to t of 72 h).
Despite the fact that micafungin demonstrated clinical efficacy in
pivotal trials at current regimens, the use of a loading dose of
FIG 2 Mean plasma concentration-time curve of micafungin (100 mg/day) on day 7.
FIG 3 Mean plasma concentration-time curve of micafungin (100 mg/day)
on days 3 and 7.
Lempers et al.
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micafungin in ICU patients should be evaluated to increase expo-
sure on the first day of therapy.
We did not observe altered micafungin PK in a small subcohort
of patients with renal dysfunction (modification of diet in renal
disease [MDRD], 10 to 30 ml/min/1.73 m2) or in those receiving
renal replacement therapy (see Table S1 in the supplemental ma-
terial), which confirms previous findings in the literature (20–22,
36, 37).
The clinical consequence of the lower exposure in this cohort is
subject to debate, as in the setting of lower exposure, efficacy
might be compromised (38, 39). Recently, Andes et al. (40) dem-
onstrated by analysis of two micafungin phase III trials that the
probability of mycological cure in adult patients with invasive
candidiasis or candidemia receiving micafungin therapy (55%
were admitted to the ICU) was higher if the patient attained an
AUC/MIC ratio between 3,000 and 12,000 compared to a ratio of
3,000 (98.0% versus 85.1%, respectively). The authors con-
cluded that if the MIC was0.06 mg/liter, the vast majority of the
patients would attain the lower target of 3,000 (11, 12, 40). A
subgroup analysis of the 55% ICU patients in this cohort is lacking
in this paper. Unfortunately, no hypothesis can be generated from
this paper on the efficacy of micafungin in the selected group of
patients in the ICU.
In our population with median AUC0 –24s of 78.6 mg · h/liter
and 65.7 mg · h/liter on days 3 and 7, respectively, setting a target
AUC/MIC ratio of 3,000 and a clinical breakpoint (CBP) of 0.03
mg/liter would result in 75% of our population not being able to
attain the target value (AUC0 –24,90 mg · h/liter) on both days on
which PK was measured for micafungin. Obviously, using higher
CBPs would result in even larger proportions of patients not
achieving this PK-PD target. The success of therapy in our cohort
might be driven by pathogens with low MICs (0.03 mg/liter),
which would result in 100% target attainment. However, data on
susceptibility are lacking in this research, and conclusions on the
exposure response in relation to the susceptibility of the pathogen
as drawn by Andes et al. (40) cannot be substantiated.
Unfortunately, in daily practice, we are confronted with a crit-
ical delay in obtaining MICs from cultured species. In the absence
of these susceptibility data/MICs, the population average expo-
sure of healthy volunteers might serve as a reference value, as these
average concentrations represent the best-case scenario (for the
standard dose). An individual who achieves this exposure is less
likely to demonstrate a suboptimal clinical response. Further in-
ducing the likeliness of achieving mycological cure, higher stan-
dard doses of micafungin in this patient population could be con-
sidered, as it has been confirmed that micafungin has a favorable
tolerability profile and displays dose-proportional linear pharma-
cokinetics (19, 20, 41). Last, to avoid concentration-dependent
therapeutic failure, therapeutic drug monitoring of micafungin
(TDM) could be a valuable tool in this especially vulnerable pa-
tient population.
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